*Press releases are taken from the company websites.
*Titles may be translated independently.
*Please be aware that, since data is collected automatically, there is a possibility of omissions occurring.
*We would like to kindly inform you that we do not collect all press releases from companies.
| Ticker Code | Date | Title | Link |
|---|---|---|---|
| TSE:2269 | 12/5/2025 | Posting of interim report for FY2025 | https://www.meiji.com/investor/library/report/ |
| TSE:2269 | 12/5/2025 | Notice regarding partial changes (expansion) to shareholder benefit system (265KB) | https://www.meiji.com/pdf/news/2025/251205_01.pdf |
| TSE:4502 | 12/5/2025 | Completion of strategic partnership with Innovent Biologics for next-generation solid tumor therapeutics Completion of strategic partnership with Innovent Biologics for next-generation solid tumor therapeutics | https://www.takeda.com/jp/newsroom/newsreleases/2025/closing-partnership-innovent/ |
| TSE:4506 | 12/5/2025 | Concerning donations for the damage caused by the large-scale fire in Saganoseki, Oita City | https://www.sumitomo-pharma.co.jp/news/20251205.html |
| TSE:4534 | 12/5/2025 | Announcement of NHI drug price listing and new release of high-purity EPA preparation “Ethyl icosapentate granular capsules “Mochida”” | https://ssl4.eir-parts.net/doc/4534/tdnet/2728194/00.pdf |
| TSE:4540 | 12/5/2025 | R&D briefing video released | https://c-hotline.net/Viewer/Default/5718d0e1efc5e586dc68a9e5dfa8c81beab4 |
| BIIB | 12/5/2025 | Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting | https://investors.biogen.com/news-releases/news-release-details/biogen-and-stoke-therapeutics-present-data-further-support |
| TSE:2269 | 12/4/2025 | Introducing the latest Oral Maps® with twice the sensor sensitivity to the Meiji Application Center, which enables quantitative evaluation of textures such as "melt in the mouth" and "smoothness" of whipped cream etc. - Strengthening recipe and menu propo | https://www.meiji.co.jp/corporate/pressrelease/2025/12_01/ |
| TSE:2269 | 12/4/2025 | Announcement regarding investment in Lyric Bio for commercialization of next-generation human immunoglobulin manufacturing technology (392KB) | https://www.meiji-seika-pharma.co.jp/pressrelease/2025/detail/pdf/251204_01.pdf |
| TSE:4516 | 12/4/2025 | Practicing regional DX as a DX promotion hub from Kyoto, won 2nd place in the industry category and regional DX producer★★ at "JAPAN DX Player AWARD 2025" | https://www.nippon-shinyaku.co.jp/news/news.php?id=3594 |
| TSE:4516 | 12/4/2025 | CAP-1002: Announcement of topline data from Capricor's clinical phase III study (HOPE-3 study) | https://www.nippon-shinyaku.co.jp/news/news.php?id=3598 |
| TSE:4540 | 12/4/2025 | The R&D briefing session script has been released. | https://www.tsumura.co.jp/ir/library/briefing-materials/item/20251204_RandDscript_j.pdf |
| TSE:4540 | 12/4/2025 | R&D briefing materials have been released. | https://www.tsumura.co.jp/ir/library/briefing-materials/item/20251204_RandDslide_j.pdf |
| TSE:4886 | 12/4/2025 | December 4, 2025 Announcement of new release of Leuprorelin Acetate SR Injection Kit 11.25mg “Asuka”198.5 KB | https://www.aska-pharma.co.jp/news/filedownload.php?name=b6273631152a459d6c4644e1c908e5d9.pdf |
| AZN | 12/4/2025 | AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH | https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2025/astraZeneca-advances-haematology-cell-therapy-ambition-with-largest-ever-presence-at-ash.html |